Citius Oncology, Inc. (CTOR) Stock

NASDAQ: CTORHealthcare company in the specialty & generic drug manufacturers industry, based in Cranford, NJ.

Citius Oncology stock price chart

CTOR interactive chart →

CTOR stock quote & key statistics

Citius Oncology earnings per share

Income →
Earnings per share

Citius Oncology revenue & net income

Income →
RevenueNet income

Citius Oncology annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$24.8M-$0.34
FY2024$0-$21.1M-$0.08
FY2023$0-$12.7M$0.20
FY2022$0-$10.9M—

Fiscal year ending September 30. Source: company filings via EODHD.

About Citius Oncology, Inc.

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.

Citius Oncology stock FAQ

What is the Citius Oncology stock ticker symbol?

Citius Oncology, Inc. trades on the NASDAQ under the ticker symbol CTOR.

What sector and industry is Citius Oncology in?

Citius Oncology, Inc. is classified in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry.

What were Citius Oncology's revenue and earnings last fiscal year?

Citius Oncology reported revenue of $0 and net income of -$24.8M in fiscal 2025, with earnings per share of -$0.34.

When did Citius Oncology go public?

Citius Oncology stock began trading on December 8, 2022.

Drug Manufacturers - Specialty & Generic stocks

All Healthcare stocks →